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Introduction: The Mo.Ma proximal embolic protection system provide neuro-
protection during all phases of the carotid artery stenting (CAS) procedure. However,
cerebral intolerance is not an infrequent occurrence with this approach. In most of the
cases, intolerance is a benign phenomenon which resolves quickly. However, in some
cases, the symptoms may persist and this requires further action. There is no much
information about relationship between procedural cerebral intolerance and carotid
back pressure during the occlusion. Here, we report our experience about this rela-
tionship in 25 patients undergoing CAS with the Mo.Ma device.
Method: During the procedure, cerebral protection was achieved by means of balloon
occlusion of the common and external carotid artery with a Mo.Ma System. The
patients’ neurologic status was assessed during the intervention. The blood pressure at
the carotid bifurcation was measured before the onset of carotid balloon occlusion.
Afterwards, carotid back pressures at the carotid bifurcation were measured imme-
diately after the occlusion of carotid balloon and immediately before the deﬂation of
carotid balloon during the procedure.
Results: The procedure was technically successful in all cases. No strokes, deaths, or
myocardial infarctions occurred. The average duration of carotid occlusion was 8.2
minutes. The blood pressure measured in the carotid artery was on average 13027
mm Hg before the onset of carotid balloon occlusion. Carotid artery back pressure was
5315 mm Hg immediately after occlusion of the carotid balloon. Of the 25 patients,
4 patients (16%) experienced cerebral intolerance. The patients with cerebral intol-
erance demonstrated back pressures of 20, 25 and 21and 20 mmHg, respectively.
Mean carotid artery back pressure was 21.52 mmHg in these patients during the
occlusion and back pressures continued to fall at the end of occlusion (185 mmHg)
(immediately before the deﬂation of carotid balloon). However, in the patients without
cerebral intolerance, mean carotid back pressure was 5315 mm Hg and back pres-
sure did not change signiﬁcantly at the end of occlusion (immediately before the
deﬂation of carotid balloon). As expected, the carotid back pressure was under 30
mmHg in the patients developing symptoms during the occlusion. However, 4
asymptomatic patients had also a distal back pressure under 30 mmHg during the
occlusion.
Conclusion: One of the most important concerns with the use of Mo.Ma proximal
embolic protection device is possible cerebral intolerance. This usually consists to
transient neurological symptoms which may occur during the proximal occlusion. In
the patients undergoing CAS with the Mo.Ma system, a commonly held notion is that
back pressure of <30 mm Hg cause symptoms of cerebral intolerance during the
occlusion. However, our study showed that a low carotid back pressure of <30 mm
Hg may not always result in symptoms of intolerance during occlusion.
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Introduction: Closure devices are well established as an alternate to mechanical
compression or surgical closure after some percutaneous intervention. The single
ProGlide, the Prostar device and the double ProGlide devices can be used for 5F to 8F,
8.5F-24F and 9F-21F access sites, respectively. The potential for adverse outcomes is
greater with an increased-diameter femoral access sheath, given the increase risk of
hemorrhage in the event of device failure. We evaluated the incidence and types of
complications encountered with use of percutaneous suture-mediated closure devices
(ProGlide and Prostar) in conjunction with the preclose technique to seal puncture
sites after some percutaneous interventions.
Methods: In this single center retrospective study, our medical records were reviewed
for the patients having access site closures with the single Perclose ProGlide, double
Proglide and Prostar devices performed in conjunction with some percutaneous
interventions (TAVI, balloon aortic valvuloplasty, carotid stenting, renal stenting,
renal denervation, and coronary interventions). Procedure success was deﬁned as
hemostasis with the preclose technique without the need for any ancillary procedure.
Access-related major adverse events included perforation, bleeding, lower leg
ischemia, pseudoaneurysm, arteriovenous ﬁstula, hematoma, embolization, laceration,
femoral artery thrombosis, nerve injury, infection, or death owing to an access site
injury.
Results:We identiﬁed 251 consecutive patients, between June 2011 and June 2013 in
whom single Proglide, double Proglides and Prostar closure devices were used during
98 peripheral vascular interventions (renal, carotid), 53 coronary interventions, 46
TAVI procedure and 7 aortic balloon valvuloplasty procedures. In the single Proglide,JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/ORAdouble Proglide and Prostar closure devices, procedure success were achieved in 167
(98.8%) of 169 patients, in 49 (94.2%) of 52 patients and in 1 (96,6%) of 30 femoral
sites, respectively. In the single Proglide group (n¼169), there were only 2 device
failures managed with manual compression. Minor complications included two groin
hematomas and two cases of persistent pain at the arteriotomy site. In the double
Proglides group, there were three device failures treated with surgical closure or
Prostar (n¼1). Minor complications included two groin hematomas and two cases of
persistent pain at the arteriotomy site. In the Prostar group, there were one device
failure treated with surgical closure and, two minor complications included two cases
of persistent pain at the puncture site.
Conclusion: In our study, vascular complications were considerably low in the three
groups. We have also found the double ProGlide technique to be easy to use, safe,and
feasible for access sites 9F.Valvular Heart Diseases
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Background: In some patients, including elderly, physically inactive or obese
patients, it is difﬁcult to assess the symptoms because of inactivity in patients with
chronic mitral regurgitation. A noninvasive marker that shows early changes in the
cardiovascular system would therefore be helpful in evaluating patients with MR. The
aim of this study was to evaluate the association between plasma pro-adrenomedullin
levels and MR and its prognostic value as indicator of cardiovascular prognosis in
patients with moderate/severe MR.
Methods: A total of 221 consecutive patients (129 women [58.4%]; mean age
61.612.5 years) with isolated and organic moderate MR, moderate to severe MR or
severe MR were included in the study. Patients were categorized according to the
NYHA functional class. We assessed and graded the severity of MR using a multi-
parametric approach. Pro-adrenomedullin was measured with ELISA method. Patients
were followed-up by outpatient assessments and telephone contact.
Results: Baseline demographic and clinical characteristics of the study population are
listed in Table 1. Echocardiographic and laboratory parameters of patients with mitral
regurgitation and comparison between asymptomatic and symptomatic patients are
listed Table 2. Pro-adrenomedullin was signiﬁcantly higher among symptomatic
MR patients when compared with asymptomatic patients (p<0.001). Median pro-
adrenomedullin levels increased signiﬁcantly with NYHA class (p<0.001, Figure 1)
and with higher degrees of MR (p<0.001, Figure 2). Increased levels of serum
creatinine, pro-adrenomedullin level, male gender, reduced LVEF, and higher
NYHA functional classes were signiﬁcantly associated with an increased risk of
death during follow-up. In multivariate analysis, LVEF and NYHA class were the
only independent predictors of death (Table 3).
Conclusion: Pro-adrenomedullin levels can help to identify patients with asymp-
tomatic moderate/severe mitral regurgitation from the symptomatic ones. This may be
useful in the optimal timing of mitral valve surgery in certain subset of patients.LS C77
